EGFR and neoplasm: Later, a pooled analysis of RCTs confirmed the predictive value of primary tumor location [48], and the recent Japanese PARADIGM trial prospectively showed improved OS with anti-EGFR therapy compared to BEV, particularly in left-sided tumors [49].